During the last session, EyePoint Pharmaceuticals Inc (NASDAQ:EYPT)’s traded shares were 0.82 million, with the beta value of the company hitting 1.52. At the end
During the last session, EyePoint Pharmaceuticals Inc (NASDAQ:EYPT)’s traded shares were 1.13 million, with the beta value of the company hitting 1.51. At the end
EyePoint Pharmaceuticals Inc (NASDAQ:EYPT)’s traded shares stood at 0.67 million during the last session, with the company’s beta value hitting 1.49. At the close of
During the last session, EyePoint Pharmaceuticals Inc (NASDAQ:EYPT)’s traded shares were 0.77 million, with the beta value of the company hitting 1.48. At the end
In the last trading session, 1.58 million shares of the EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) were traded, and its beta was 1.48. Most recently the company’s
EyePoint Pharmaceuticals Inc (NASDAQ:EYPT)’s traded shares stood at 0.66 million during the last session, with the company’s beta value hitting 1.48. At the close of
In last trading session, EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) saw 0.38 million shares changing hands with its beta currently measuring 1.49. Company’s recent per share price
EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) has a beta value of 1.50 and has seen 1.1 million shares traded in the last trading session. The company, currently
In the last trading session, 0.87 million shares of the EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) were traded, and its beta was 1.53. Most recently the company’s
In the last trading session, 1.27 million shares of the EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) were traded, and its beta was 1.54. Most recently the company’s
Marketing Sentinel delivers exclusive content, news, articles, and comprehensive coverage of events in the USA and worldwide with a commitment to reliability, objectivity, and timeliness.
© 2024, Powered by Smart TechOne
